The Hipra company , located in Amer (Girona) , plans to produce 400 million doses of its vaccine against covid-19 during 2022.
The ambitious goal has been enough to attract the attention of the Prime Minister, Pedro Sánchez , who visited the facilities of the firm this Friday in order to support the projects of this ambitious firm, which moves from the area of animal health to human with the hope of providing an effective vaccine next year.
It is a recombinant protein vaccine that has been designed to optimize its safety and induce a powerful neutralizing immune response to the covid-19 virus.
In addition, it will be kept between 2 and 8 degrees Celsius, which will facilitate its logistics and distribution.Hipra ranks sixth in the world ranking of vaccines for animal health and is progressively specializing in the development of vaccines for humans.
The clinical trials will begin in June and it is expected that they will be completed successfully to start production in October of this year, with the aim of launching its commercialization at the end of 2021.
subject to obtaining the appropriate authorizations. According to Hipra’s current projections, 400 million doses are expected to be produced during 2022, and by 2023 1,200 million doses could be reached.